In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.

The rationale for the study, according to the authors, is that “Nearly 2% of the US population received a prescription for ...

HealthDay News — The US Food and Drug Administration re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss medication tirzepatide is over.

Medications like semaglutide and tirzepatide have gained significant attention for their impressive weight-loss effects, but they do much more than just helping you shed pounds. Let’s dive into ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight. At the Cardiometabolic Health Congress ...

Hines Jr Professor of Medicine at Yale University School of Medicine Tirzepatide decreases heart size to improve cardiac structure, function In a secondary analysis of the SUMMIT trial ...

Tirzepatide decreases heart size to improve cardiac structure, function In a secondary analysis of the SUMMIT trial, researchers looked at the effect of the combined GLP-1 and GIP receptor agonist ...